Glimepiride lmg, Metformin Hcl (Sustained Released) 50mg + Voglibose 0.2mg Tablets (Uncoated Bilayered)

Glimepiride lmg, Metformin Hcl (Sustained Released) 50mg + Voglibose 0.2mg Tablets (Uncoated Bilayered) is a bilayered tablet formulated with Glimepiride lmg, Metformin Hcl (Sustained Released) 50mg + Voglibose 0.2mg ( ). The listed active ingredient profile is Glimepiride lmg; Metformin Hcl; Voglibose, placing the product in the oral antidiabetic category. The formulation contains one or more oral glucose-lowering medicines used in clinician-directed management of type 2 diabetes mellitus. The source indicates sustained release; uncoated; bilayered characteristics, which should be retained exactly because release technology can affect administration and product performance. For website cataloguing, the composition, strength, dosage form and formulation characteristics should be displayed prominently and consistently. The product description should remain factual and should not include unapproved cure, superiority, guaranteed-result or broad therapeutic claims. Clinical selection should depend on diagnosis, patient-specific factors, contraindications, concomitant medicines and professional judgement. Prescription status, warnings, interactions, adverse effects and dosing or application instructions must be checked against the current approved product label. Manufacturer, licence, storage, shelf-life, reconstitution where applicable, and market-specific regulatory details should be added only from verified product documentation.